korrents

korrents · piece

A new breed of biotech

Alex Telford · 17 Sept 2024

Read the piece on atelfo.github.io ↗

1 korrent from this piece ↓

Alex Telford did not write this page.

Every claim below was made in this piece, quoted word for word and numbered in the order the piece makes them, so you can read it there rather than take our word for it. The sentence above each quote is our reading of the claim, not their wording. Each quote was checked against a stored copy of the page at build time; where the two differ, the quote is the fact.

  1. Another challenge for Class II biotechs is that even if you have a nifty computational drug discovery platform, you are still often bottlenecked by the rest of the drug development process. It takes 1,000 (or more!) small steps to advance a drug through discovery, development, and past the regulators.

Keep reading

The other pieces are the ones whose claims are worded most like this one's. That measures language, not agreement: they may argue the opposite.